{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:16:33Z","timestamp":1782537393927,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.bcp.2023.115493","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T15:56:35Z","timestamp":1678290995000},"page":"115493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo"],"prefix":"10.1016","volume":"210","author":[{"given":"Yongxia","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6212","key":"10.1016\/j.bcp.2023.115493_b0005","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.1253735","article-title":"The melanoma revolution: from UV carcinogenesis to a new era in therapeutics","volume":"346","author":"Lo","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bcp.2023.115493_b0010","first-page":"236","article-title":"Treatment of, European consensus-based interdisciplinary guideline for melanoma","volume":"170","author":"Garbe","year":"2022","journal-title":"Part 1: Diagnostics: Update 2022, Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2023.115493_b0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"10.1016\/j.bcp.2023.115493_b0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2023.115493_b0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2023.115493_b0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2023.115493_b0035","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.bcp.2023.115493_b0040","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2023.115493_b0045","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","article-title":"Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients","volume":"25","author":"Sullivan","year":"2019","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bcp.2023.115493_b0050","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2020.12.004","article-title":"Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study","volume":"32","author":"Gogas","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2023.115493_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105295","article-title":"Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux","volume":"163","author":"Xia","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"7330","key":"10.1016\/j.bcp.2023.115493_b0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2023.115493_b0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2023.115493_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100988","article-title":"Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas","volume":"56","author":"Morschhauser","year":"2022","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.bcp.2023.115493_b0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13148-020-0818-7","article-title":"H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade","volume":"12","author":"Hoffmann","year":"2020","journal-title":"Clin. Epigenetics."},{"issue":"2","key":"10.1016\/j.bcp.2023.115493_b0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/13543776.2021.1841167","article-title":"Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)","volume":"31","author":"Dockerill","year":"2021","journal-title":"Expert. Opin. Ther. Pat."},{"issue":"5","key":"10.1016\/j.bcp.2023.115493_b0085","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.bcp.2023.115493_b0090","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115493_b0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bcp.2023.115493_b0100","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"1","key":"10.1016\/j.bcp.2023.115493_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms7051","article-title":"The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors","volume":"6","author":"Zingg","year":"2015","journal-title":"Nat. Comm."},{"issue":"1","key":"10.1016\/j.bcp.2023.115493_b0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/pcmr.12280","article-title":"EZH2: an emerging role in melanoma biology and strategies for targeted therapy","volume":"28","author":"Tiffen","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"issue":"3","key":"10.1016\/j.bcp.2023.115493_b0115","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/0008-5472.CAN-15-1141","article-title":"Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene MutationsOncogenic KRAS Modulates EZH2 Expression in NSCLC","volume":"76","author":"Riquelme","year":"2016","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bcp.2023.115493_b0120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/PAS.0000000000000125","article-title":"Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma","volume":"38","author":"Sasaki","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115493_b0125","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1089\/scd.2012.0172","article-title":"H3K9me-enhanced DNA hypermethylation of the p16INK4a gene: an epigenetic signature for spontaneous transformation of rat mesenchymal stem cells","volume":"22","author":"Zheng","year":"2013","journal-title":"Stem Cells Dev."},{"issue":"Suppl 3","key":"10.1016\/j.bcp.2023.115493_b0130","doi-asserted-by":"crossref","first-page":"S667","DOI":"10.1245\/s10434-013-3135-y","article-title":"Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis","volume":"20","author":"Nakagawa","year":"2013","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115493_b0135","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/15384047.2016.1167291","article-title":"Role of EZH2 histone methyltrasferase in melanoma progression and metastasis","volume":"17","author":"Mahmoud","year":"2016","journal-title":"Cancer Biol. Ther."},{"issue":"33","key":"10.1016\/j.bcp.2023.115493_b0140","doi-asserted-by":"crossref","first-page":"25967","DOI":"10.1039\/C5RA02365C","article-title":"Design, synthesis and biological evaluation of novel 1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinolins as potential EZH2 inhibitors","volume":"5","author":"Zhang","year":"2015","journal-title":"RSC Advances"},{"key":"10.1016\/j.bcp.2023.115493_b0145","doi-asserted-by":"crossref","first-page":"20864","DOI":"10.1038\/srep20864","article-title":"Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer","volume":"6","author":"Song","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2023.115493_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.08.012","article-title":"Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway","volume":"169","author":"Zhu","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115493_b0155","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1021\/acs.jmedchem.1c01876","article-title":"Design and Synthesis of Dual EZH2\/BRD4 Inhibitors to Target Solid Tumors","volume":"65","author":"Guo","year":"2022","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2023.115493_b0160","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1074\/mcp.M115.053363","article-title":"Quantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma","volume":"15","author":"Sengupta","year":"2016","journal-title":"Mol. Cell Proteomics"},{"issue":"4","key":"10.1016\/j.bcp.2023.115493_b0165","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/path.5094","article-title":"Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target","volume":"245","author":"Cao","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcp.2023.115493_b0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-8722-6-19","article-title":"Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers","volume":"6","author":"Li","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115493_b0175","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2023.115493_b0180","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1038\/s41598-017-03362-z","article-title":"EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion","volume":"7","author":"Yi","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2023.115493_b0185","first-page":"422","article-title":"EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2\/-9 pathway","volume":"8","author":"Chien","year":"2018","journal-title":"Am. J. Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2023.115493_b0190","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2217\/fon-2020-0781","article-title":"Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives","volume":"17","author":"Simeone","year":"2021","journal-title":"Future Oncol."},{"issue":"23","key":"10.1016\/j.bcp.2023.115493_b0195","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.7150\/jca.63415","article-title":"EZH2-mediated epigenetic suppression of lncRNA PCAT18 predicts a poor prognosis and regulates the expression of p16 by interacting with miR-570a-3p in gastric cancer","volume":"12","author":"Zhu","year":"2021","journal-title":"J. Cancer"},{"issue":"7015","key":"10.1016\/j.bcp.2023.115493_b0200","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature03094","article-title":"G1 cell-cycle control and cancer","volume":"432","author":"Massagu\u00e9","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115493_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101674","article-title":"Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement","volume":"37","author":"Nolfi-Donegan","year":"2020","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115493_b0210","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cell.2015.10.001","article-title":"Mitochondrial ROS signaling in organismal homeostasis","volume":"163","author":"Shadel","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bcp.2023.115493_b0215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","article-title":"Oxidative Stress in Cancer","volume":"38","author":"Hayes","year":"2020","journal-title":"Cancer cell"},{"issue":"11","key":"10.1016\/j.bcp.2023.115493_b0220","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc3803","article-title":"Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?","volume":"14","author":"Sabharwal","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2023.115493_b0225","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1021\/acs.jmedchem.2c00047","article-title":"Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects","volume":"65","author":"Xia","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2023.115493_b0230","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41374-021-00700-8","article-title":"Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies","volume":"102","author":"Qi","year":"2022","journal-title":"Lab. Invest."},{"issue":"5","key":"10.1016\/j.bcp.2023.115493_b0235","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.bcp.2023.115493_b0240","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embj.201694058","article-title":"A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination","volume":"36","author":"Wang","year":"2017","journal-title":"EMBO J"},{"key":"10.1016\/j.bcp.2023.115493_b0245","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1039\/D0CC04670A","article-title":"The discovery of SKLB-0335 as a paralog-selective EZH2 covalent inhibitor","volume":"57","author":"Zhang","year":"2021","journal-title":"Chem. Commun. (Camb)"},{"issue":"5","key":"10.1016\/j.bcp.2023.115493_b0250","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","article-title":"Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2023.115493_b0255","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a first-in-class EZH2 selective degrader","volume":"16","author":"Ma","year":"2020","journal-title":"Nat. Chem. Biol."},{"issue":"13","key":"10.1016\/j.bcp.2023.115493_b0260","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1073\/pnas.1814634116","article-title":"EZH1\/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer","volume":"116","author":"Wassef","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"12","key":"10.1016\/j.bcp.2023.115493_b0265","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1021\/acs.jmedchem.0c02261","article-title":"Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction","volume":"64","author":"Du","year":"2021","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bcp.2023.115493_b0270","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1021\/acs.jmedchem.1c00226","article-title":"Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders","volume":"64","author":"Tomassi","year":"2021","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bcp.2023.115493_b0275","doi-asserted-by":"crossref","first-page":"10167","DOI":"10.1021\/acs.jmedchem.1c00460","article-title":"Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma","volume":"64","author":"Tu","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:20:33Z","timestamp":1736360433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":55,"alternative-id":["S0006295223000849"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115493","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115493"}}